To bring this back to clinical relevance: even if the exact magnitude of GCG-mediated thermogenesis is debatable, the hepatic effects are unambiguous and potentially more important clinically.

Glucagon is the primary signal for hepatic glycogenolysis and fatty acid oxidation. The liver fat reduction data from retatrutide Phase 2 (≥70% reduction in liver fat in over 80% of participants) far exceeds what's seen with pure GLP-1 agonists. This isn't a subtle effect — it's a dramatic, clinically meaningful improvement in hepatic steatosis.

Whether you want to call hepatic fatty acid oxidation "thermogenesis" is partly semantic. The energy from those oxidized fatty acids has to go somewhere — some is captured as ATP, some is dissipated as heat. The net effect is that fat stores in the liver are mobilized and depleted. That's the GCG component earning its keep, regardless of the BAT question.

One more data point worth considering: the heart rate increase seen with retatrutide (~3-5 bpm above semaglutide/tirzepatide levels) may be partially a reflection of increased sympathetic tone driven by GCG thermogenesis. There's a correlation in the Phase 2 data between the magnitude of heart rate increase and the degree of weight loss, though correlation doesn't imply causation.

The heart rate effect also has safety implications. The TRIUMPH program includes cardiovascular monitoring, and the CVOT data will be critical for demonstrating that the incremental heart rate increase doesn't translate to adverse cardiovascular outcomes.

So to summarize my takeaway from this discussion: the GCG thermogenesis story is real but probably more modest in humans than the preclinical data suggested. The bigger clinical wins from the GCG component are likely liver fat reduction, prevention of metabolic adaptation during weight loss, and possibly additional satiety signaling.

The "triple agonist burns more calories" narrative is a useful simplification for patients but scientifically it's more nuanced than that. Fair summary?

That's a very fair summary. The GCG component's value is real but multifaceted — it's not just "burning more calories" but rather a combination of hepatic fat mobilization, metabolic rate preservation, and possibly enhanced satiety. The thermogenesis narrative is catchy but oversimplified.

What excites me most is that we're still in the early innings of understanding how these three receptors interact. The full picture of GLP-1/GIP/GCG co-agonism will take years of clinical data and mechanistic studies to work out. We're watching an entirely new chapter of metabolic pharmacology being written in real time.